Veru Inc. (VERU:NSD) is scheduled to announce its quarterly earnings results before the market opens on Thursday, May 11th. The company is expected to report a loss of ($0.33) per VERU stock share for the quarter, according to analysts.
Previous Quarter Earnings:
In the last earnings report on February 9th, Veru reported a loss of ($0.46) in earnings per share (EPS) for the quarter, missing analysts’ estimates of ($0.38) by ($0.08). The company had a negative return on equity of 119.37% and a negative net margin of 412.01%. Veru generated revenue of $2.51 million for the quarter, compared to the consensus estimate of $5.05 million.
VERU Stock Price Analysis:
As of Thursday, VERU stock opened at $1.27 with a 50-day moving average of $1.76 and a two-hundred-day moving average of $5.01. The company has a market capitalization of $105.00 million, a price-to-earnings ratio of -0.89, and a beta of -0.22. Veru’s 52-week low is $0.93, and the 52-week high is $24.55.
According to Stock Target Advisor, Veru stock has an average rating of “Strong Buy” with a consensus target price of $12.89.
VERU Stock-Analyst Ratings:
Analysts forecast Veru to post a loss of $1 EPS for the current fiscal year and $1 EPS for the next fiscal year. Despite the challenges, Wall Street analysts remain optimistic about the company’s future growth prospects.
HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Veru in a research note on Wednesday, April 12th. Oppenheimer also reduced their price objective on Veru from $14.00 to $9.00 but maintained an “outperform” rating on the stock.
Hedge Funds & Institutional Holdings:
Several institutional investors and hedge funds have recently modified their holdings of Veru. XTX Topco Ltd raised its stake in shares of Veru by 18.7% during the first quarter, while Money Concepts Capital Corp, Squarepoint Ops LLC, Principal Financial Group Inc., and LPL Financial LLC all acquired new stakes in Veru. Institutional investors and hedge funds now own 48.87% of the VERU stock.
Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms.
The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.